Navigation Links
PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
Date:6/1/2009

x of Severity (CDEIS) was observed in the 500 mg QD group compared to placebo (CDEIS decrease of -8.4 vs. -1.1 for placebo, p=0.049). C-reactive protein (CRP) results confirmed the effect of 500 mg QD Traficet-EN. Traficet-EN may offer a new orally available treatment option with a favorable side effect profile to patients with this chronic gastrointestinal disease.

"Targeting the CCR9 chemokine receptor represents a new and highly specific approach to treating patients with Crohn's disease and potentially ulcerative colitis," said Pirow Bekker, M.D., Ph.D., Senior Vice President, Medical and Clinical Affairs of ChemoCentryx. "No cure exists for inflammatory bowel diseases and many patients do not respond to or cannot tolerate current treatment options, including the newer biologics such as anti-Tumor Necrosis Factor (TNF) agents, which need to be injected or infused. There was no evidence of an increased risk of infection with Traficet-EN in PROTECT-1. This safety and efficacy profile may translate into a meaningful treatment option for patients."

"These data highlight a year of unparalleled clinical development progress by the ChemoCentryx team. This is true not only for our CCR9 program, but throughout our entire pipeline," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. "Traficet-EN results announced today underscore our leadership position in CCR9-based therapeutics for the treatment of inflammatory bowel diseases."

The randomized, placebo-controlled, double-blind PROTECT-1 clinical trial of more than 430 patients is comprised of three discrete phases which allows for evaluation of efficacy and safety of Traficet-EN in inducing a clinical response or remission, as well as maintaining response/remission in Crohn's disease over a combined total of 12 months. The Induction Phase of the study is followed by a four-week, open label 'Active Period', during which all subje
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
2. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
3. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
5. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
6. TNFerade(TM) Phase III Data Presented at ASCO
7. Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
8. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
9. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
10. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
11. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 2014  Semler Scientific, Inc. (Nasdaq: ... company that develops patented products that assist healthcare ... today reported financial results for the third quarter ... "In the third quarter of 2014, ... M.D., chief executive officer of Semler.  "We moved ...
(Date:10/31/2014)... , Oct. 31, 2014  Australian biopharmaceutical company Specialised ... (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine, will ... patients with metastatic pancreatic cancer from 1 November. ... cancer is the 5 th most common cause ... all cancer deaths, with the lowest 5-year survival of ...
(Date:10/31/2014)... -- Investor-Edge has initiated coverage on the ... Isis Pharmaceuticals Inc. (NASDAQ: ISIS ), Halozyme ... Inc. (NASDAQ: ACAD ), and Synta Pharmaceuticals ... can be accessed at: http://investor-edge.com/register . ... at 4,566.14, up 0.37%, the Dow Jones Industrial Average ...
Breaking Medicine Technology:Semler Reports Third Quarter 2014 Financial Results 2Semler Reports Third Quarter 2014 Financial Results 3Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 2Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 3Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 4Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 5Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 6Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 7Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 8Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 2Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 3Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 4Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 5
... Reportlinker.com announces that a new market research ... Global Intraocular Lenses Industry ... the worldwide markets for Intraocular Lenses in US$ ... Lenses, and Foldable Intraocular Lenses. The report provides ...
... New Mexico Software, Inc. (OTC Bulletin ... and solutions that enable improved and faster communication within the healthcare ... diagnostic imaging services for the Heart Institute of the Caribbean ... Jamaica. HIC is now sending nuclear and other exams ...
Cached Medicine Technology:Reportlinker Adds Global Intraocular Lenses Industry 2New Mexico Software Launches Company's First International Telemedicine Service 2New Mexico Software Launches Company's First International Telemedicine Service 3
(Date:10/31/2014)... 2014 Uniwigs.com newly arrived flip in ... model can comfortably attach itself around people’s heads with a ... generation of flip-in extensions comes with adjustable loops, which are ... part and customers can now adjust the wire to best ... people apply this new generation of flip ins, they simply ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 Med-Care Diabetic ... on the highest principles of patient care and service, ... leading health and wellness website, to provide an online ... diabetes. , The Diabetes Health Center will provide ... for those living with diabetes. Content will feature advice ...
(Date:10/31/2014)... 2014 (HealthDay News) -- A few simple steps can help ... sleep expert says. "Adjusting to the end of Daylight ... handling the time change in the spring. The main reason ... fall time change," Dr. Praveen Rudraraju, director of the Center ... N.Y., said in a hospital news release. The many ...
(Date:10/31/2014)... By Dennis Thompson ... -- The World Bank pledged Thursday an additional $100 million ... West Africa. The money, which brings the World Bank,s ... to attract more foreign health care workers to the three ... "The world,s response to the Ebola crisis has increased significantly ...
(Date:10/31/2014)... to generic hormone therapy medicines improves the chances that ... a new study found. "We know that hormone ... reduce recurrence by up to 50 percent," study leader ... Columbia University Medical Center in New York City, said ... by our group and others has shown that a ...
Breaking Medicine News(10 mins):Health News:UniWigs Unveiles New Generation of Flip In Hair Extensions 2Health News:Med-Care Diabetic & Medical Supplies, Inc. Partners with Lifescript to Provide Online Diabetes Health Center 2Health News:Med-Care Diabetic & Medical Supplies, Inc. Partners with Lifescript to Provide Online Diabetes Health Center 3Health News:Make the Most of This Weekend's Time Change 2Health News:World Bank Pledges $100M More to Fight West Africa's Ebola Outbreak 2Health News:Generic Drugs May Help Breast Cancer Patients Stick to Therapy 2
... FLORHAM PARK, N.J., Jan. 6 Managed Health Care ... Butterfield, RN, has joined MHA, Inc. as the new ... newly created role Pegeen will have executive responsibility for ... Michael J. Sicilian, President of MHA, commented, "The creation ...
... Web-Based Community for Parents of Children with DisabilitiesNEWTON, ... community for parents of disabled children, today announced ... to assist parents of children with disabilities, the ... resource library for families. ChildRC ( www.ChildRC.com ) ...
... Inc. (TSX: IM) ("IMRIS" or the "Company") today ... Australia for its IMRISneuro surgical imaging solution, thereby ... Canberra Hospital has chosen a two-room configuration of ... a larger Australian Capital Territory infrastructure project. , ...
... Jan. 6, 2009 The Procter & Gamble Company,(NYSE: ... have reached a settlement in the lawsuit P&G,filed on ... trade dress and,patent infringement on its Olay Regenerist brands. ... Fruit of the Earth recognized the validity of,P&G,s rights ...
... means condition could be biologically driven, researchers say , , ... traumatized by sexual, physical or psychological abuse are more ... research suggests. , The study also states that ... be based in biology. The reason: There appears to ...
... PET Infusion System to Compare Techniques for Patient ... signed a research agreement with the University of ... MEDRAD Intego(TM) PET Infusion System. The researchers ... control the radioactive dose delivered during PET imaging ...
Cached Medicine News:Health News:MHA Announces Pegeen Butterfield, RN as Senior Vice President of Trade Relations 2Health News:ChildRC.com Launches The Child Resource Center 2Health News:Childhood Trauma Tied to Chronic Fatigue Syndrome 2Health News:Childhood Trauma Tied to Chronic Fatigue Syndrome 3Health News:MEDRAD Sponsors PET Research with University of Zurich 2Health News:MEDRAD Sponsors PET Research with University of Zurich 3Health News:MEDRAD Sponsors PET Research with University of Zurich 4
... System aids in the rapid, detection of ... available in vitro system that uniquely simulates ... primary hemostasis. The system measures platelet function ... environment of a partially occluded blood vessel. ...
... A complete range of automatic systems for ... 1 mL of blood. With the introduction ... the clinical diagnostic market a truly revolutionary ... technical limitation associated with the traditional ESR ...
... NEW VACUETTE® erythrocyte sedimentation rate ... help. The new generation unites the ... with whole range of additional innovations ... the erythrocyte sedimentation rate. Cost effectiveness ...
Blood sedimentation rate analysis...
Medicine Products: